Adaptimmune Therapeutics (ADAP) AI Stock Analysis

• Market Cap: $19.80M
• Dividend Yield: N/A
• Average Volume (3M): 35.61M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.03
• Revenue Growth: -53.61%
• EPS Growth: -93.14%
• Country: US
• Employees: 506
• Sector: Healthcare
• Sector Strength: 41
• Industry: Biotechnology
• EPS (TTM): -0.12
• Shares Outstanding: 265,051,600
• 10 Day Avg. Volume: 86,608,458
• 30 Day Avg. Volume: 35,610,987
• PEG Ratio: N/A
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: 4.34
• Enterprise Value/Revenue: 0.48
• Enterprise Value/Gross Profit: 0.49
• Enterprise Value/Ebitda: -1.64
• 1Y Price Target: $0.36
• Price Target Upside: 350.00% Upside
• Rating Consensus: Moderate Sell
• Number of Analyst Covering: 7

• Rating: 39 Underperform
• Price Target: $0.00 ▼(-100.00% Downside)

The overall stock score reflects significant financial challenges, including persistent losses and negative equity, which are the most impactful factors. Technical indicators suggest bearish momentum, and valuation metrics indicate potential undervaluation due to financial instability. Despite positive operational achievements, financial concerns and strategic restructuring weigh heavily on the score.

Positive Factors

Operational Efficiency

The company is not experiencing any manufacturing or reimbursement issues, suggesting strong potential for revenue growth.

Revenue Growth

Management anticipates full-year 2025 Tecelra revenue of $35-45M, surpassing the previous sellside consensus estimate of $25M.

Negative Factors

Asset Sale Impact

The sale of key assets leaves the company with preclinical assets that are still in the early stages of development.

Financial Challenges

Concerns around loan repayment and a depressed biotech market are impacting the company's outlook.

Workforce Reduction

The company announced plans to reduce its workforce by 62% as well as the departure of several C-suite executives.

Adaptimmune Therapeutics Business Overview & Revenue Model

Company Description

Adaptimmune Therapeutics plc is a clinical-stage biotechnology company focused on the development of T-cell therapies to treat cancer. Headquartered in Oxford, UK, the company specializes in the field of immunotherapy, particularly utilizing its proprietary T-cell receptor (TCR) technology to engineer T-cells that can target and destroy cancer cells. Adaptimmune is primarily engaged in developing therapies for various cancers, including solid tumors and hematological malignancies, with key products like SPEAR T-cell therapies that are designed to enhance the body’s immune response against cancer.

How the Company Makes Money

Adaptimmune Therapeutics generates revenue primarily through partnerships and collaborations with pharmaceutical companies, as well as through grants and funding from governmental and non-governmental organizations. The company may receive milestone payments as it progresses its therapies through clinical trials, and royalties from any future sales of products that arise from its collaborations. Additionally, Adaptimmune may also explore options for licensing its technology to other companies, which can provide further financial inflows. The success of its therapies in clinical trials and subsequent commercialization efforts are critical for its earning potential.

Adaptimmune Therapeutics Financial Statement Overview

Summary

Adaptimmune Therapeutics shows significant revenue growth, but persistent losses, negative equity, and weak cash flows highlight substantial risks. The company's financial health is compromised by high operational costs and liabilities, requiring strategic measures to improve profitability and liquidity.

Income Statement

Adaptimmune Therapeutics shows a significant improvement in revenue over the years, with a recent TTM revenue of $179.6M compared to $3.96M in 2020. However, the company consistently reports negative EBIT and net income, reflecting ongoing challenges in managing operational costs and achieving profitability. Gross profit margins have improved, but the net profit margin remains negative, indicating continued losses. Despite revenue growth, profitability concerns significantly impact the score.

Balance Sheet

The company's balance sheet reveals high financial risk, with negative stockholders' equity in the latest TTM, indicating liabilities exceed assets. The debt-to-equity ratio is unfavorable due to negative equity, and the return on equity is also negative, reflecting ongoing losses. Cash reserves have declined, adding to financial instability. The company's high liabilities and negative equity present substantial financial risks.

Cash Flow

Cash flow analysis shows negative operating and free cash flows, indicating the company's operations are not generating cash. The free cash flow growth rate is negative, suggesting increased cash consumption. The operating cash flow to net income ratio is unfavorable, reflecting inefficiencies in cash generation relative to reported losses. Despite some financing inflows, the cash flow position remains weak, impacting stability.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	178.03M	60.28M	27.15M	6.15M	3.96M
Gross Profit	177.96M	50.42M	-100.58M	-104.94M	-87.61M
EBITDA	-52.66M	-128.20M	-155.59M	-155.68M	-125.81M
Net Income	-70.81M	-113.87M	-165.46M	-158.09M	-130.09M
Balance Sheet
Total Assets	245.96M	282.62M	328.92M	469.55M	451.14M
Cash, Cash Equivalents and Short-Term Investments	151.60M	146.94M	204.60M	369.58M	368.22M
Total Debt	74.21M	25.23M	23.08M	25.47M	23.71M
Total Liabilities	234.11M	243.10M	247.04M	263.58M	109.92M
Stockholders Equity	11.85M	39.51M	81.88M	205.96M	341.23M
Cash Flow
Free Cash Flow	-75.93M	-145.76M	-171.51M	1.95M	-56.50M
Operating Cash Flow	-73.21M	-140.88M	-141.77M	10.73M	-53.59M
Investing Cash Flow	-58.95M	176.54M	89.14M	75.80M	-278.92M
Financing Cash Flow	78.75M	880.00K	12.87M	3.29M	340.05M

Adaptimmune Therapeutics Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.08
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Positive
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ADAP, the sentiment is Negative. The current price of 0.08 is below the 20-day moving average (MA) of 0.16, below the 50-day MA of 0.22, and below the 200-day MA of 0.43, indicating a bearish trend. The MACD of -0.05 indicates Positive momentum. The RSI at 29.03 is Positive, neither overbought nor oversold. The STOCH value of 18.37 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ADAP.

Adaptimmune Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	65 Neutral	¥341.96B	11.05	-0.16%	2.40%	9.83%	-10.32%
ADAG	44 Neutral	$89.98M	―	-63.24%	―	-87.65%	11.76%
CLSD	40 Underperform	$34.07M	―	91.63%	―	-44.63%	26.80%
ADAP	39 Underperform	$19.80M	―	-1341.37%	―	-53.61%	-93.14%
CABA	39 Underperform	$121.65M	―	-76.34%	―	―	-41.69%
CNTX	37 Underperform	$61.00M	―	-37.25%	―	―	62.83%
JSPR	35 Underperform	$42.81M	―	-146.87%	―	―	-17.96%

Adaptimmune Therapeutics Corporate Events

Adaptimmune Announces Termination of Chief Medical Officer

On August 7, 2025, Adaptimmune announced the termination of Dr. Elliot Norry as Chief Medical Officer, effective August 8, 2025, due to redundancy. Dr. Norry will receive a severance package including a year’s salary and healthcare coverage. Similarly, Dr. Joanna Brewer’s role as Chief Scientific Officer will end on August 31, 2025, with a similar severance arrangement. Gavin Wood’s termination as Chief Financial Officer, initially announced in December 2024, will also conclude on August 31, 2025, with a severance package including a year’s salary and a pro rata bonus. These changes reflect a strategic restructuring within the company.

The most recent analyst rating on (ADAP) stock is a Buy with a $3.00 price target. To see the full list of analyst forecasts on Adaptimmune Therapeutics stock, see the ADAP Stock Forecast page.

Adaptimmune Sells Cell Therapy Assets for $55 Million

On July 31, 2025, Adaptimmune Therapeutics completed a significant transaction involving the sale of its cell therapy assets to USWM CT, LLC, receiving $55 million and potential future milestone payments. This transaction also allowed Adaptimmune to settle its $29.1 million debt with Hercules Capital, thereby improving its financial position and potentially impacting its future operations and market strategy.

The most recent analyst rating on (ADAP) stock is a Buy with a $3.00 price target. To see the full list of analyst forecasts on Adaptimmune Therapeutics stock, see the ADAP Stock Forecast page.

Adaptimmune Sells Cell Therapy Assets to US WorldMeds

On July 27, 2025, Adaptimmune Therapeutics entered into an agreement to sell its cell therapy assets, including TECELRA, lete-cel, afami-cel, and uza-cel, to US WorldMeds for $55 million, with potential additional payments of up to $30 million based on milestone achievements. This transaction is part of a broader restructuring plan by Adaptimmune to maximize value from its remaining assets and involves significant workforce reductions. The restructuring will see key executives depart and is expected to incur pre-tax costs of approximately $7-8 million. The transaction aims to ensure the continued availability of TECELRA to patients and support the development of other therapies by US WorldMeds.

The most recent analyst rating on (ADAP) stock is a Buy with a $3.00 price target. To see the full list of analyst forecasts on Adaptimmune Therapeutics stock, see the ADAP Stock Forecast page.

Adaptimmune Settles Litigation with M.D. Anderson Cancer Center

On July 16, 2025, Adaptimmune Therapeutics plc entered into a settlement agreement with The University of Texas M.D. Anderson Cancer Center to resolve litigation related to a Strategic Alliance Agreement from 2016. The settlement, which involves financial payment obligations, is not expected to have a material adverse effect on Adaptimmune’s financial position or operations.

The most recent analyst rating on (ADAP) stock is a Buy with a $3.00 price target. To see the full list of analyst forecasts on Adaptimmune Therapeutics stock, see the ADAP Stock Forecast page.

Adaptimmune’s Annual Meeting Focuses on Shareholder Engagement

Adaptimmune Therapeutics held its annual general meeting on May 29, 2025, where shareholders voted on several resolutions, including the re-election of directors and the approval of the company’s 2025 Employee and Non-Employee Share Option Schemes. The meeting also determined that advisory votes on executive compensation will be held annually until 2031, reflecting the company’s commitment to shareholder engagement and governance practices.

The most recent analyst rating on (ADAP) stock is a Buy with a $3.00 price target. To see the full list of analyst forecasts on Adaptimmune Therapeutics stock, see the ADAP Stock Forecast page.